Adalta有限公司宣布与上海细胞治疗集团签署合作协议，双方将共同开发创新药物Bzds1901。根据协议条款，Adalta将获得该药物在大中华区（包括中国大陆、香港、澳门和台湾）以外所有全球市场的独家开发和商业化权利。此次合作标志着Adalta在拓展全球细胞治疗市场方面迈出重要一步，也为Bzds1901的国际化布局奠定基础。
Adalta有限公司宣布与上海细胞治疗集团签署合作协议，双方将共同开发创新药物Bzds1901。根据协议条款，Adalta将获得该药物在大中华区（包括中国大陆、香港、澳门和台湾）以外所有全球市场的独家开发和商业化权利。此次合作标志着Adalta在拓展全球细胞治疗市场方面迈出重要一步，也为Bzds1901的国际化布局奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.